PMID: 15389118Sep 25, 2004Paper

Tissue factor: (patho)physiology and cellular biology

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
Karl-Erik Eilertsen, Bjarne Østerud

Abstract

The transmembrane glycoprotein tissue factor (TF) is the initiator of the coagulation cascade in vivo. When TF is exposed to blood, it forms a high-affinity complex with the coagulation factors factor VII/activated factor VIIa (FVII/VIIa), activating factor IX and factor X, and ultimately leading to the formation of an insoluble fibrin clot. TF plays an essential role in hemostasis by restraining hemorrhage after vessel wall injury. An overview of biological and physiological aspects of TF, covering aspects consequential for thrombosis and hemostasis such as TF cell biology and biochemistry, blood-borne (circulating) TF, TF associated with microparticles, TF encryption-decryption, and regulation of TF activity and expression is presented. However, the emerging role of TF in the pathogenesis of diseases such as sepsis, atherosclerosis, certain cancers and diseases characterized by pathological fibrin deposition such as disseminated intravascular coagulation and thrombosis, has directed attention to the development of novel inhibitors of tissue factor for use as antithrombotic drugs. The main advantage of inhibitors of the TF*FVIIa pathway is that such inhibitors have the potential of inhibiting the coagulation cascade at its ear...Continue Reading

References

Apr 1, 1975·The Journal of Clinical Investigation·J R MaynardY Nemerson
Dec 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·B Osterud, S I Rapaport
Jul 1, 1975·British Journal of Haematology·R P RiversW L Weston
Nov 1, 1992·The Journal of Clinical Investigation·P J Shultz, L Raij
Dec 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·B M MuellerW Ruf
Aug 1, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·I K JangJ N Wilcox
Sep 2, 1991·Science·D Gailani, G J Broze
Sep 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·R Bach, D B Rifkin
Jun 1, 1989·Molecular and Cellular Biology·S A GregoryT S Edgington
Oct 3, 1989·Biochemistry·L R PaborskyJ R Swartz
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·J N WilcoxD Gordon
Feb 1, 1989·Thrombosis Research·E M ConwayW H Konigsberg
Aug 25, 1987·Biochemistry·E M ScarpatiJ E Sadler
Aug 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·E K SpicerW H Konigsberg
Jan 1, 1988·CRC Critical Reviews in Biochemistry·R R Bach
Jul 1, 1988·Somatic Cell and Molecular Genetics·F T KaoS D Carson
Oct 1, 1987·Thrombosis Research·K L FisherR M Lawn
Oct 1, 1971·Proceedings of the Society for Experimental Biology and Medicine·R G LernerK Lange
Apr 1, 1972·Proceedings of the Society for Experimental Biology and Medicine·J Niemetz, V Herbert
Aug 1, 1995·Arteriosclerosis, Thrombosis, and Vascular Biology·D KirchhoferH R Baumgartner
May 1, 1993·The Journal of Clinical Investigation·J D MarmurM B Taubman
May 1, 1995·Arteriosclerosis, Thrombosis, and Vascular Biology·G C Parry, N Mackman
Apr 1, 1994·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·C P van der LogtR M Bertina

❮ Previous
Next ❯

Citations

Feb 20, 2019·Frontiers in Immunology·Marion MussbacherJohannes A Schmid

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.